KV Pharmaceutical steps toward comeback

GMP expert Lachman Consultants is overseeing production re-start at embattled specialty drug maker KV Pharmaceutical, which is preparing for an FDA inspection required before it can resume product shipments. KV is rehiring production employees to produce test batches of drugs, a step toward what it expects to be a successful FDA inspection.

KV projects it will be shipping before the year is out, according to a report in the St. Louis Business Journal.

In March, the U.S. Department of Justice sued the drug maker to block it from manufacturing and distributing adulterated and unapproved drugs, prompted by an FDA finding of GMP noncompliance, says Reuters. The DoJ action followed a recall of several meds by KV unit Ethex, which was followed by investigations of KV by the FDA and the Security and Exchange Commission, plus lawsuits from shareholders, former employees and patients.

- here's the Journal report
- see the Reuters item

Related Articles:
KV agrees to FDA plan for resuming work
KV Pharma suspends operations, delays Gestiva
Shareholders file suit against KV Pharma

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.